BACKGROUND: In comparison to normal brain tissue, glioblastomas exhibit significantly increased glucose uptake. Brain edema is a common complication during adjuvant chemoradiotherapy, leading to a requirement for glucocorticoid treatment. Glucocorticoid treatment frequently causes considerable deregulation of blood glucose levels. Therefore, episodes of hyperglycemia may contribute to radio- and/or chemoresistance. PATIENTS AND METHODS: This study comprises a retrospective analysis of the influence of hyperglycemic episodes (HEs) during adjuvant therapy on the overall survival of 106 glioblastoma multiforme patients. RESULTS: The occurrence of one or more deregulated blood glucose value(s) > 10 mM is associated with a reduction in median overall survival from 16.7 to 8.8 months. A significantly poorer overall survival of patients with hyperglycemia could also be detected in subgroup analyses of patients with complete tumor resection and complete treatment according to the EORTC 22891/26891 trial protocol, as well as in a multivariate Cox proportional hazards analysis. A history of diabetes mellitus had no influence on prognosis. DISCUSSION: Our data suggest that the observed negative impact of elevated blood glucose levels on overall survival may not solely be explained by the patients' poorer general condition; the elevated blood glucose concentration itself may play a pathogenetic role. This could be due to increased activity of antioxidant systems, elevated expression of DNA damage response proteins and protection of hypoxic tumor cells against apoptosis combined with hypoxia-mediated radioresistance. CONCLUSION: A possible prognostic impact of elevated blood glucose levels during the period of adjuvant (chemo-) radiotherapy of glioblastoma should be evaluated in a prospective clinical trial.
BACKGROUND: In comparison to normal brain tissue, glioblastomas exhibit significantly increased glucose uptake. Brain edema is a common complication during adjuvant chemoradiotherapy, leading to a requirement for glucocorticoid treatment. Glucocorticoid treatment frequently causes considerable deregulation of blood glucose levels. Therefore, episodes of hyperglycemia may contribute to radio- and/or chemoresistance. PATIENTS AND METHODS: This study comprises a retrospective analysis of the influence of hyperglycemic episodes (HEs) during adjuvant therapy on the overall survival of 106 glioblastoma multiformepatients. RESULTS: The occurrence of one or more deregulated blood glucose value(s) > 10 mM is associated with a reduction in median overall survival from 16.7 to 8.8 months. A significantly poorer overall survival of patients with hyperglycemia could also be detected in subgroup analyses of patients with complete tumor resection and complete treatment according to the EORTC 22891/26891 trial protocol, as well as in a multivariate Cox proportional hazards analysis. A history of diabetes mellitus had no influence on prognosis. DISCUSSION: Our data suggest that the observed negative impact of elevated blood glucose levels on overall survival may not solely be explained by the patients' poorer general condition; the elevated blood glucose concentration itself may play a pathogenetic role. This could be due to increased activity of antioxidant systems, elevated expression of DNA damage response proteins and protection of hypoxic tumor cells against apoptosis combined with hypoxia-mediated radioresistance. CONCLUSION: A possible prognostic impact of elevated blood glucose levels during the period of adjuvant (chemo-) radiotherapy of glioblastoma should be evaluated in a prospective clinical trial.
Authors: Felix Sahm; David Capper; Astrid Jeibmann; Antje Habel; Werner Paulus; Dirk Troost; Andreas von Deimling Journal: Arch Neurol Date: 2011-12-12
Authors: W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch Journal: J Natl Cancer Inst Date: 1993-05-05 Impact factor: 13.506
Authors: Rachel L Derr; Xiaobu Ye; Melissa U Islas; Serena Desideri; Christopher D Saudek; Stuart A Grossman Journal: J Clin Oncol Date: 2009-01-12 Impact factor: 44.544
Authors: Ulrike G A Sattler; Sandra S Meyer; Verena Quennet; Christian Hoerner; Hannah Knoerzer; Christian Fabian; Ala Yaromina; Daniel Zips; Stefan Walenta; Michael Baumann; Wolfgang Mueller-Klieser Journal: Radiother Oncol Date: 2009-12-28 Impact factor: 6.280
Authors: Thomas N Seyfried; Laura Shelton; Gabriel Arismendi-Morillo; Miriam Kalamian; Ahmed Elsakka; Joseph Maroon; Purna Mukherjee Journal: Neurochem Res Date: 2019-04-25 Impact factor: 3.996
Authors: Yuanying Gong; Yufang Ma; Maksim Sinyuk; Sudan Loganathan; Reid C Thompson; Jann N Sarkaria; Wenbiao Chen; Justin D Lathia; Bret C Mobley; Stephen W Clark; Jialiang Wang Journal: Neuro Oncol Date: 2015-07-01 Impact factor: 12.300